Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

Benzer Materyaller

• Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
  Yazar:: Cannon, Christopher P., ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
  Yazar:: Colhoun, Helen M., ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
  Yazar:: Kastelein, John J. P., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial
  Yazar:: Gregory P. Geba, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-09-01)
• Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
  Yazar:: Stroes, Erik, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)